Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears / OncoDaily
oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance
Saturday, February 28, 2026, 3:22 am / permalink 19937 / 9 stories in 16 days
Teladoc Health reports slower growth, offers cautious 2026 outlook as it shifts telehealth model / Fierce
fiercehealthcare - Teladoc Health reported better-than-expected fourth quarter financial results with both revenue and earnings exceeding analysts' expectations, driving a 15% jump in the company's stock Thursday.
#healthcare #governmentpolicy #digitalhealth #healthcarefinance
Saturday, February 28, 2026, 3:22 am / permalink 19936 / 3 stories in 16 days
CFO Mark Kaye to take the helm at Carelon in leadership shake-up at Elevance Health / Fierce
fiercehealthcare - Elevance Health Chief Financial Officer Mark Kaye will grow his list of duties to include oversight of Carelon, the company announced Thursday.
#healthcare #digitalhealth #behavioralhealth #healthcarefinance
Saturday, February 28, 2026, 2:21 am / permalink 19934 / 6 stories in 16 days
First-ever in-utero stem cell therapy for fetal spina bifida repair shows safe results / Medical Express
medicalxpress - A Phase I clinical trial published in The Lancet has shown that combining stem cell therapy with standard fetal surgery before birth is a safe and promising approach to treat myelomeningocele, a severe form of spina bifida. This is the first time live ste…
#healthcare #biotech #drugdevelopment #infanthealth
Saturday, February 28, 2026, 1:22 am / permalink 19931 / 2 stories in 16 days
Microplastics discovered in prostate tumors / Medical Express
medicalxpress - Small fragments of plastic were found in 9 out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, a new study finds. The small, single-center study was led by researchers at NYU Langone Health, its …
#healthcare #publichealth #oncology
Saturday, February 28, 2026, 12:23 am / permalink 19928 / 4 stories in 16 days
Boehringer wins accelerated approval for first-line use of lung cancer drug / Endpoints
Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda #oncology
Saturday, February 28, 2026, 12:23 am / permalink 19927 / 9 stories in 16 days
Novartis to build $23B radioligand therapy site / Beckers
Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance
Saturday, February 28, 2026, 12:23 am / permalink 19926 / 3 stories in 16 days
Patient dies in MacroGenics' cancer study, FDA puts trial on hold / Endpoints
Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #oncology
Saturday, February 28, 2026, 12:23 am / permalink 19925 / 3 stories in 16 days
Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus / OncoDaily
oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #digitalhealth #healthcarefinance
Friday, February 27, 2026, 11:22 pm / permalink 19912 / 6 stories in 16 days
UHS posts 11.5% operating margin in 2025 as net income jumps 30% / Beckers
Andrew Cass / beckershospitalreview - King of Prussia, Pa.-based Universal Health Services recorded a net income of $1.5 billion in 2025, up from $1.1 billion in 2024, according to its Feb. 25 financial report. Eight things to know: 1. The for-profit system reported an operating income of $2 …
#healthcare #publichealth #governmentpolicy #behavioralhealth #hospitaloperations #healthcarefinance
Friday, February 27, 2026, 11:25 am / permalink 19887 / 10 stories in 17 days
Cancer blood test fails to catch disease earlier in major study / Medical Express
medicalxpress - A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it.
#healthcare #publichealth #governmentpolicy #biotech #medicaldevices #oncology
Thursday, February 26, 2026, 7:24 pm / permalink 19851 / 7 stories in 18 days
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial / Endpoints
Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...
#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #drugdevelopment
Thursday, February 26, 2026, 7:23 am / permalink 19788 / 12 stories in 18 days
More Research, Less Cancer: £250m raised to transform the future of cancer research / Cancer Research UK
Charlotte Mathé / cancerresearchuk - We’ve reached an incredible moment - £250m raised for our More Research, Less Cancer campaign. This milestone brings us more than halfway to our £400m goal and accelerates our mission to prevent, detect and treat cancer earlier and more effectively. The p…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology
Tuesday, February 24, 2026, 1:24 pm / permalink 19675 / 53 stories in 20 days
FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026 / OncoDaily
oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda
Tuesday, February 24, 2026, 12:25 pm / permalink 19669 / 6 stories in 20 days
ChatGPT Health performance in a structured test of triage recommendations / Nature
Ashwin Ramaswamy / nature - Nature Medicine, Published online: 23 February 2026; doi:10.1038/s41591-026-04297-7A stress test of ChatGPT Health triage revealed missed high-risk emergencies and inconsistent activation of suicide-crisis safeguards, raising safety concerns for consumer-…
#healthcare #publichealth #governmentpolicy #fda #digitalhealth #medicaldevices
Tuesday, February 24, 2026, 11:25 am / permalink 19660 / 18 stories in 20 days
Gilead to acquire cell therapy manufacturer for $7.8B / Beckers
Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #fda #oncology
Monday, February 23, 2026, 4:23 pm / permalink 19605 / 7 stories in 21 days
Justice Department sues OhioHealth over alleged anticompetitive insurer contracts / Healthcare Dive
Sydney Halleman / healthcaredive - The DOJ filed a lawsuit last week accusing OhioHealth of leveraging its market power to force insurers to include its providers in their networks.
Monday, February 23, 2026, 2:23 pm / permalink 19594 / 7 stories in 21 days
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin / ESMO
esmo - Findings from the KEYNOTE-905/EV-303 study
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Monday, February 23, 2026, 2:22 am / permalink 19558 / 15 stories in 21 days
Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC / OncoDaily
oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Monday, February 23, 2026, 2:22 am / permalink 19557 / 23 stories in 21 days
Brain injury is almost ten times more common in unhoused people. Addressing it is key to reducing homelessness / Medical Express
medicalxpress - On any given night, 60,000 people in Canada will go to sleep homeless. Research estimates that more than half of them have had a brain injury at one point in their lives, most of them being injured before becoming homeless. An estimated 22.5% live with mo…
#healthcare #publichealth #governmentpolicy
Saturday, February 21, 2026, 6:23 pm / permalink 19543 / 4 stories in 23 days